Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | PTP4A3 | O75365 | 2/20 | 0.54 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 3/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18893873 | 0.83 | ERN1 (0.52) | L3MBTL1SMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL20982624 | 0.82 | ERN1 (0.59) | L3MBTL1SMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL865350 | 0.82 | MAOA (0.58) | RAB9AMAPTNPC1CCNB2CDK1 | |
| SCHEMBL3615463 | 0.82 | MAOB (0.58) | L3MBTL1SMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL31113771 | 0.82 | ERN1 (0.54) | L3MBTL1SMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL1539204 | 0.81 | SMN1; SMN2 (0.52) | L3MBTL1SMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL1067302 | 0.81 | ALDH1A1 (0.58) | L3MBTL1SMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL13932656 | 0.80 | MAOB (0.61) | L3MBTL1SMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL433401 | 0.79 | CCNB2 (0.72) | L3MBTL1SMN1; SMN2RAB9AMAPTNPC1 | |
| SCHEMBL29537861 | 0.79 | CCNB2 (0.72) | L3MBTL1SMN1; SMN2RAB9AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 704 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5620987-A | Amino acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 1997-04-15 | — | — | US | claimed |
| US-5446161-A | Protease inhibitor, viricides | HOFFMANN-LA ROCHE INC. (US) | 1995-08-29 | — | — | US | claimed |
| EP-0346847-B1 | Amino acid derivatives | HOFFMANN LA ROCHE (CH) | 1994-05-11 | — | — | EP | claimed |
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | claimed |
| US-12043639-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-4384508-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024031051-A1 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024006937-A1 | LIPID COMPOSITIONS FOR IN VIVO DELIVERY | Life Technologies Corporation (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20240000966-A1 | Lipid Compositions For In Vivo Delivery | Life Technologies Corporation | 2024-01-04 | — | — | US | disclosed |
| US-11850237-B2 | Compounds and methods for treating influenza | ROMARK LABORATORIES L.C. (US) | 2023-12-26 | — | — | US | disclosed |
| WO-2023018990-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2023-02-16 | — | — | WO | disclosed |
| EP-2445349-B1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | ROMARK LABORATORIES LC (US) | 2022-02-09 | — | — | EP | disclosed |
| US-5157041-A | Viricides | HOFFMANN-LA ROCHE INC. (US) | 1992-10-20 | — | — | US | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008698-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008699-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008688-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| EP-0432694-A2 | Aminoalcohols | F. HOFFMANN-LA ROCHE AG (CH) | 1991-06-19 | — | — | EP | disclosed |
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043639-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | L3MBTL1 635/4885SMN1; SMN2 2031/4885RAB9A 2936/4885 |
| US-20240000966-A1 | Lipid Compositions For In Vivo Delivery | CHMP4B, LIPA, CETP | L3MBTL1 1134/4885SMN1; SMN2 2806/4885RAB9A 701/4885 |
| US-11850237-B2 | Compounds and methods for treating influenza | HIF1AN, HAVCR2, NEU1 | L3MBTL1 4193/4885SMN1; SMN2 4684/4885RAB9A 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.